512P - VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer agents
Soft Tissue Sarcomas
Presenter Ji Young Moon
Citation Annals of Oncology (2016) 27 (suppl_9): ix163-ix168. 10.1093/annonc/mdw597
Authors J.Y. Moon, S. Baek, H. Ryu, Y.S. Choi, I. Song, H. Yun, D. Jo, S. Kim, H.J. Lee
  • Internal Medicine, Chungnam National University, 35015 - Daejeon/KR

Abstract

Background

Soft tissue sarcomas (STS) are rare and heterogeneous malignancies. Although 40% of patients experience tumor recurrence, the available treatment options are limited after failure of conventional first-line cytotoxic chemotherapy. We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated STS.

Methods

We analyzed the medical records of patients with advanced or relapsed STS who had undergone VIP treatment as second-line or more chemotherapy between January 2000 and December 2015. The patients were treated with a combination of etoposide (100 mg/m2 for 5 days), ifosfamide (2,000 mg/m2 for 2 days), and cisplatin (20 mg/m2 for 5 days) once every 4 weeks. Treatment response, progression free survival (PFS), and overall survival (OS) were analyzed in all patients and between responder and non-responder groups (responders showed a tumor response to any prior systemic chemotherapy before VIP).

Results

Twenty-four patients with a median age of 50 years (range: 20–68 years) were treated with VIP. Eleven (45.8%) patients were male and seven (29.2%) received two or more chemotherapy regimens before VIP. Median PFS was 3.7 months (95% confidence interval [CI], 1.3–6.1 months) and median OS was 10.0 months (95% CI, 6.6–13.5). The overall response rate was 37.5% (complete remission, n = 1; partial remission, n = 8), and the disease control rate was 50%. The responder group showed better PFS (7.7 vs. 3.0 months; P = 0.101) and significantly improved OS (11.0 vs. 8.8 months; P = 0.039; 95% CI, 1.0–7.6) compared to those of non-responders. All patients reported some grade of hematological toxicity. The most frequently encountered hematological toxicity was neutropenia (any grade, 77.7%; grade 3 or 4, 74.0%).

Conclusions

VIP might be effective in patients with previously treated STS.

Clinical trial indentification

Legal entity responsible for the study

This study was approved by the Institutional Review Board of Chungnam National University Hospital.

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.